INTRODUCTION {#S1}
============

Limitations on health care resources necessitate careful focus on activities that lead to the greatest improvement in patient outcomes.

Several studies have shown that hospital-based clinical pharmacist services improve patient outcomes via reducing length of stay (LOS), serious adverse advents, morbidity and mortality.[@B1]-[@B4] Furthermore, studies have also shown that the incorporation of pharmacists into care teams can significantly reduce health care costs[@B1],[@B2],[@B4]-[@B6] and because of their training in pharmacology and familiarity with medications, pharmacists perform certain activities with more accuracy in the clinical setting.[@B7] Observational data exists documenting clinical pharmacists' activities[@B8], however, pharmacists have their own perceptions about the impacts of the activities they perform, and these perceptions may influence how they spend their time providing direct patient care. Despite the importance of aligning pharmacists' time with activities deriving the most impact, there is a paucity of literature on the correlations between pharmacists' perceptions of the impacts of the activities that they perform, how they actually spend their time and how these align with published evidence for impacts on patient outcomes. In addition, pharmacists' own perceptions of what constitutes quality care in their practice area are a possible foundation for quality measurement.

The purpose of this study was to reveal hospital pharmacists' perceptions of the impacts of their clinical activities and to characterize the correlation between the activities performed and both their perceptions of and the published evidence for their impacts on patient care. Such data could help identify opportunities for realignment of pharmacists' activities to optimize patient outcomes.

METHODS {#S2}
=======

 {#S3}

### Study Design and Organization {#S4}

This study consisted of observational qualitative interviews, quantitative questionnaires, and a systematic literature review. Ethical and administrative approval for the research was obtained.

### Study Population {#S5}

Study participants consisted of a convenience sample of clinical pharmacists employed by Vancouver Coastal Heath and Providence Health Care Pharmacy Services, a multi-institution regionalized service delivery organization. Participants were selected by the investigators to be representative of multiple sites, practice settings and training levels.

Participants were enrolled over a five month period from November 2008 to March 2009. Pharmacists were eligible to participate if they had direct patient care responsibilities at least 50% of the time, had a minimum of 1 year of experience as a clinical pharmacist, and provided written consent.

### Pharmacist Activities {#S6}

A compendium of 35 discreet clinical pharmacist activities was developed by reviewing published literature, compiling the investigators' own experience and interviewing a pilot cohort of clinical pharmacists. The first questionnaire asked each study subject to estimate how much time they allocate to each activity on a daily basis, using seven time categories ranging from none to "more than 3 hours/day". The responses to the first questionnaire were elicited during individual meetings between each participant and one of the study investigators. In this meeting, demographic data (experience, main care areas, and training) was collected and a 30-40 minute recorded, semi-structured, qualitative interview was also conducted.

### Published Evidence of Impact on Patient Outcomes {#S7}

A review of published literature for the period 1978 to April 2009 was conducted to identify discreet hospital pharmacist activities evaluated for evidence of impact on clinical outcomes. PubMed, Embase, International Pharmaceutical Abstracts, and Cochrane Database of Systematic Reviews were searched using the terms: *pharmacist, clinical pharmacy, pharmaceutical care, pharmacy services, mortality, morbidity, adverse reaction, outcome* and each previously-identified activity individually. Hand searches of bibliographies of relevant articles were performed. Studies presented in abstracts, letters to the editor, editorials, reviews, pediatric studies, and studies occurring in the primary care setting were excluded from this review. Methods of identified studies were reviewed for required criteria, including pharmacy service or intervention described, presence of a control group, and identification of patient-specific clinical outcomes as endpoints.

The patient-specific clinical outcomes were arranged into a hierarchy of impacts, from lowest to highest (0 to 7) as follows: no benefit, improve patient satisfaction, improve quality of life, reduce adverse events, reduce morbidity, reduce LOS, decrease hospital readmissions, and decrease mortality. The investigators created this hierarchy based on consensus since no relevant validated or generally-accepted outcomes hierarchy including both clinical and humanistic outcomes exists. Where conflicting evidence existed in published literature the greatest impact identified was the impact score assigned. This optimistic assignment was chosen because most published studies were not powered to find a significant difference in clinical outcomes and blending studies for a particular activity was felt to give too much weight to such studies.

### Pharmacist Perceptions of Impact on Patient Outcomes {#S8}

Between two to eight weeks after the initial interview, the same pharmacists completed a second questionnaire which elicited their perceptions of the impact their clinical activities have on patient outcomes by identifying which patient outcomes from the above hierarchy are improved by each activity they perform. This questionnaire, sent electronically to each participant, was individualized in that it contained only the activities previously identified by them as being performed. Where more than one outcome could be impacted by an activity (for example, length of stay and hospital readmission could both be impacted by medication optimization), the highest-level impact was used for analysis. Time separation between the two questionnaires was designed to reduce potential bias associated with pharmacists reflecting on how much time they spend on activities and the impacts of those at the same time. The second questionnaire did not remind them of how much time they previously claimed to spend on activities, only the activities themselves.

### Analysis {#S9}

Data was extracted for analysis from the qualitative interviews, completed questionnaires, and literature review.

The primary endpoint for this study was the degree of correlation within the following three comparisons:

Pharmacists' perceptions of impacts versus the amount of time spent on the activities performed \[Comparison 1\].Published evidence of impacts versus the amount of time spent on the activities performed \[Comparison 2\].Pharmacists' perceptions of impacts versus the best available published evidence of impacts \[Comparisons 3\].

Nonparametric descriptive statistics were used to represent the time spent per activity, the perceived impact of each activity, and the correlation coefficient (Spearman's rho), for each of the comparisons (using SPSS). Strength of association was described using Cohen's criterion.[@B9]

Because not all activities had published evidence for or against them, two policies were developed to represent different interpretations of the lack of evidence. Policy 1, a conservative approach, assumed if an activity had no evidence of impact on patient outcomes, that activity had no benefit. Policy 2, a liberal approach, omitted from the analysis activities without any evidence. These policies were applied to comparisons 2 and 3 where published evidence of impact of activities was one of the comparators.

RESULTS {#S10}
=======

Twenty one pharmacists (N=21) were interviewed and completed the questionnaires with 100% completion. This represented a broad spectrum of clinical pharmacists from different hospitals, areas of practice, and years of experience ([Table 1](#T1){ref-type="table"}).

###### 

Participant characteristics (N=21)

  --------------------------- ---------------------
                              No. of participants
  Years of experience         
    \<5                       7
    5-10                      6
    \>10                      8
  Highest level of training   
    B.Sc.(Pharm)              1
    Residency                 16
    Pharm. D.                 4
  Primary area of practice    
    **Medicine**              **17**
     General medicine         4
     Psychiatry               2
     Cardiology               2
     Leukemia/BMT             2
     HIV                      2
     ICU                      1
     ER                       1
     Pediatrics               1
     Nephrology               1
     Palliative Care          1
   **Surgery**                **4**
     General surgery          2
     Vascular surgery         1
     Burns/plastics/trauma    1
  Care setting                
    Inpatient                 18
    Outpatient                3
  --------------------------- ---------------------

Thirty five clinical pharmacist activities were assessed in the first questionnaire by the participants to determine pharmacists' time allocation to those activities ([Table 2](#T2){ref-type="table"}).

###### 

Results of the two questionnaires and systematic literature review.

  ------------------------------------------------------------------ ------------------------------------ ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------
  Activity                                                           Median time (min/day) per activity   Median perceived impact (ranked score - see [Table 3](#T3){ref-type="table"})[\*](#t2fn1){ref-type="fn"}   Published impact (score assigned -- see [Table 3](#T3){ref-type="table"})
  Organization of day                                                20-39                                No benefit (0)                                                                                             N/A
  Review laboratory/microbiology                                     20-39                                ↓ LOS (5)                                                                                                  ↓ adverse events[@B15] (3)
  Review PharmaNet[†](#t2fn2){ref-type="fn"} & medication profiles   40-59                                ↓ hospital readmissions (6)                                                                                ↓ adverse events[@B15] (3)
  Chart review                                                       60-119                               ↓ hospital readmissions (6)                                                                                ↓ adverse events[@B15] (3)
  Attend patient care rounds                                         40-59                                ↓ mortality (7)                                                                                            ↓ mortality[@B11] (7)
  Medication history                                                 20-39                                ↓ morbidity /LOS (4.5)                                                                                     ↓ mortality[@B3],[@B5],[@B11] (7)
  Medication reconciliation at admission                             20-39                                ↓ LOS (5)                                                                                                  N/A
  Medication reconciliation at transfer                              1-20                                 ↓ adverse events (3)                                                                                       ↓ adverse events[@B16] (3)
  Medication reconciliation at discharge                             20-39                                ↓ hospital readmissions (6)                                                                                ↓ hospital readmissions[@B10] (6)
  Assess allergies                                                   1-20                                 ↓ LOS (5)                                                                                                  N/A
  Medication counselling                                             20-39                                ↓ hospital readmissions (6)                                                                                ↓ hospital readmissions[@B17] (6)
  Discharge counselling                                              20-39                                ↓ hospital readmissions (6)                                                                                ↓ hospital readmissions[@B10],[@B18] (6)
  Continuity of care                                                 1-20                                 ↓ hospital readmissions (6)                                                                                ↓ mortality[@B14] (7)
  Call patient's family physician                                    1-20                                 ↓ hospital readmissions (6)                                                                                N/A
  Call patient's pharmacy                                            1-20                                 ↓ hospital readmissions (6)                                                                                N/A
  Drug therapy monitoring                                            40-59                                ↓ mortality (7)                                                                                            ↓ hospital readmissions[@B19],[@B20] (6)
  Dosage adjustments                                                 20-39                                ↓ LOS (5)                                                                                                  N/A
  Initiate medications                                               20-39                                ↓ mortality (7)                                                                                            N/A
  Discontinue medications                                            20-39                                ↓ LOS (5)                                                                                                  N/A
  Monitor for side effects                                           40-59                                ↓ hospital readmissions (6)                                                                                ↓ mortality[@B11],[@B12] (7)
  Monitor for drug interactions                                      20-39                                ↓ hospital readmissions (6)                                                                                N/A
  Antibiotic optimization                                            20-39                                ↓ mortality (7)                                                                                            ↓ mortality[@B10] (7)
  IV to PO conversion                                                1-20                                 ↓ LOS (5)                                                                                                  ↓ LOS [@B21] (5)
  TDM                                                                20-39                                ↓ hospital readmissions (6)                                                                                ↓ hospital readmissions[@B10] (6)
  Warfarin dosing                                                    20-39                                ↓ LOS (5)                                                                                                  ↓ mortality[@B13] (7)
  VTE prophylaxis                                                    20-39                                ↓ hospital readmissions (6)                                                                                ↓ mortality[@B13] (7)
  Manage non-formulary meds                                          1-20                                 ↑ patient satisfaction (1)                                                                                 N/A
  Documentation on own form                                          20-39                                ↓ adverse events (3)                                                                                       N/A
  Documentation in patient's chart                                   20-39                                ↓ LOS (5)                                                                                                  N/A
  Teaching pharmacy students/ residents and Pharm D's                20-39                                No benefit (0)                                                                                             N/A
  Inservice provision                                                1-20                                 No benefit (0)                                                                                             ↓ mortality[@B11] (7)
  Literature evaluation                                              1-20                                 ↓ adverse events (3)                                                                                       N/A
  Clinical research                                                  1-20                                 ↓ mortality (7)                                                                                            ↓ mortality[@B3] (7)
  Responding to drug information questions                           10-30                                ↓ LOS (5)                                                                                                  ↓ mortality[@B3] (7)
  Management of drug protocols                                       1-20                                 ↓ LOS (5)                                                                                                  ↓ mortality[@B11] (7)
  ------------------------------------------------------------------ ------------------------------------ ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------

Where multiple impacts were identified, the highest ranked impact was used for analysis.

PharmaNet is a current record of medications dispensed over the last 14 months from community pharmacies in British Columbia.

Participants often stated they found it difficult to assign an average time to each activity, as their daily routine varies significantly, for example, more preparation time is needed earlier in the week, patient discharges requiring counselling varies, rounds may not be every day, and an occasional Special Access drug application can consume a few hours.

Pharmacists later assessed each activity they performed in terms of their perceived impact on patient outcomes ([Table 2](#T2){ref-type="table"}). Activities which participants perceived to have the greatest impact were attending patient care rounds, monitoring drug therapy, initiating drug therapy, antibiotic optimization, and clinical research. Activities believed to impart no benefit on patient outcomes were organization of day, teaching pharmacy students and residents, and providing in-services to other health care professionals.

 {#S11}

### Published Evidence of Impact {#S12}

Of 595 publications identified, 47 met the inclusion criteria. A systematic review conducted by Kaboli has previously reviewed 28 of these publications.[@B10] This literature review found 21 of the 35 activities to have positive impact on patient outcomes ([Table 2](#T2){ref-type="table"}).

Activities with the greatest impact on patient outcomes, i.e., associated with mortality reduction, included: attending patient care rounds[@B11], taking medication histories at admission[@B3],[@B5],[@B11], monitoring for side effects[@B11],[@B12], optimizing antibiotics[@B11], providing warfarin dosing services[@B13], monitoring venous thromboembolism (VTE) prophylaxis[@B13], providing in-services[@B11], conducting clinical research[@B3], responding to drug information questions[@B3], providing continuity of care[@B14], and managing drug protocols.[@B11] Examples of activities without any identified evidence on patient outcomes included assessing patients' allergies, monitoring for side effects or drug interactions, calling a family physician, organization of day, and making dosage adjustments.

Comparison 1 {#S13}
------------

Pharmacists' time spent was statistically significantly (P=0.037) and positively correlated with their perceptions of impact ([Figure 1](#F1){ref-type="fig"}). This association had moderate strength (Spearman rho=0.354) per Cohen's criteria.

![Comparison 1 of in-depth questionnaires: median time spent per activity versus median perceived impact of activity (N=35). Refer to [Table 3](#T3){ref-type="table"} for translation of axis values.](pharmpract-08-089-g001){#F1}

###### 

Legend of time categories displayed in the first questionnaire and the hierarchy of impact on patient outcomes used in this study.

  ------------------- -------------------------
  Time per activity   
  0                   Not performed
  1                   1-20 min/day
  2                   20-39 min/day
  3                   40-59 min/day
  4                   60-119 min/day
  5                   120-180 min/day
  6                   \>180 min/day
  Impact              
  0                   No benefit
  1                   ↑ patient satisfaction
  2                   ↑ quality of life
  3                   ↓ adverse events
  4                   ↓ morbidity
  5                   ↓ LOS
  6                   ↓ hospital readmissions
  7                   ↓ mortality
  ------------------- -------------------------

Comparison 2 {#S14}
------------

Pharmacists' time spent was not statistically significantly correlated with published evidence of impact ([Figure 2](#F2){ref-type="fig"}), in both policy 1 (conservative) and policy 2 (liberal) scenarios (p=0.665 and 0.523, respectively). Even if these correlation coefficients (Spearman rho=0.076 and -0.148, respectively) were statistically significant, they would indicate a weak association based on Cohen's criteria. Hence, there is not a clear association between time spent on activities and published evidence of impact of those activities.

![Comparison 2: median ranked time spent per activity versus published impact of activity, measuring with a conservative (Policy 1) and a liberal (Policy 2) approach. Refer to [Table 3](#T3){ref-type="table"} for translation of axis values.](pharmpract-08-089-g002){#F2}

Comparison 3 {#S15}
------------

Overall, pharmacists' perceptions of impacts were not statistically significantly correlated with published evidence of impacts under policy 1 (conservative) (p=0.054), however this result was on the threshold of statistical significance and the strength of association was "moderate" (Spearman rho=0.328). When a liberal measurement policy was used (policy 2), the association was not statistically significant (p=0.709), and the association was weak (Spearman rho=0.087).

Pharmacists' perceived impact and published impact were concordant (overlap of perceived impact and published impact) in 21 of the 35 activities and discordant (error bars of perceived impact do not overlap with published impact) for the other 14 ([Figure 3](#F3){ref-type="fig"}) if assuming no impact where evidence of impact is non-existent. Of the 21 activities with evidence of impact, 16 were concordant and 5 were discordant. Of the discordant activities, pharmacists perceptions exceeded published impact for 2 activities (PharmaNet/medication profile review and laboratory/microbiology review) and undervalued 3 activities compared to published literature (taking medication history, providing in-services, and answering drug information questions). We did not encounter conflicting data in relation to these activities.

![Comparison 3: published impact and pharmacists' median perceived impact (with 1st and 3rd quartile ranges as error bars) for each activity. Refer to [Table 3](#T3){ref-type="table"} for translation of y-axis values.](pharmpract-08-089-g003){#F3}

DISCUSSION {#S16}
==========

Based on this intensive evaluation of a relatively small cohort of hospital-based pharmacists, we found that there is an association between how pharmacists spend their time and their perceptions of the clinical impacts of those activities. It is less clear, however, that how they spend their time aligns well with published evidence of clinical impact. Similarly, our data do not convincingly show that pharmacists' perceptions of impact align well with published evidence of impacts, although our results were on the verge of statistical significance for a weak/moderate association here and pharmacists perceptions of impact were concordant with published evidence for the majority of activities performed.

The first finding lends validity to our methodologic approach, since it is expected that pharmacists will spend their time doing activities they believe to be most impactful. This finding also raises the hypothesis that interventions aimed at changing pharmacists perceptions of impact (e.g., education) could cause them to change how they spend their time.

The latter two findings have several implications. First, it may be important for pharmacists and their managers to better familiarize themselves with the published literature for activities which have impact and those which do not or for which there is no evidence available. Second, we did identify some specific activities which pharmacists had misperceptions about -- taking medication history, providing in-services, and answering drug information questions -- whereby realignment of their time away from other activities less justified by the published literature toward these activities could enhance their clinical impact. We suggest our findings of discordance could be very important as they represent opportunities to realign pharmacists' time and effort with activities of greater impact. Doing this would shift pharmacists from not just delivering evidenced-based therapeutics for patients but organizing ourselves to practice in an evidenced-based way by ensuring we perform those activities associated with the greatest impact. Finally, our results highlight the need for more systematic investigation into the impacts of activities performed by pharmacists, and raise questions of how pharmacists should spend their time in the absence of such evidence.

This study had limitations which should be considered. The convenience sampling may have introduced selection bias by enrolling only pharmacists willing to discuss their job and perceptions. Not all clinical areas were included, (e.g. there were no residential care, respirology, or TPN pharmacists). The hierarchy of outcomes generated for this study is subjective, but we believe, clinically sensible. In addition, when tabulating the findings of published literature, we assigned the highest impact reported, not necessarily from the most rigorously performed study. Although we believe this was the best available strategy, it exposed our results to the weaknesses in the literature.

Discreet pharmacist activities, in general, are difficult to study. Most studies have evaluated specific services pre- and post-implementation, such as the effect of an infectious disease pharmacist, rather than well defined discrete activities. In addition, the heterogeneity of the published study designs makes it impossible to conduct a meta-analysis of the data.[@B10] Some discrete activities are prerequisite steps to perform a function such as calling a family doctor (not studied) to provide continuity of care (studied), or reviewing microbiology data (shown to reduce adverse events) to optimize antibiotic therapy (shown to reduce mortality). Certain results in this study appear conflicting and may be in part due to the way we grouped discrete activities or the lack of definition or purpose of the activity. Specifically, grouping PharmaNet review with Medication profile review (perceived to reduce hospital readmissions, an overestimate) may have been misleading because this composite activity may be interpreted by some pharmacists as a required step in performing a medication history (perceived to reduce morbidity and LOS, an underestimate) and subsequent medication reconciliation (perceived to reduce LOS, not studied). Furthermore, many of the activities reported in this paper with mortality reduction were drawn from Bond's publications[@B2]-[@B5],[@B11]-[@B13], which is survey-based data, thus not as strong as data derived from a randomized controlled trial. Finally, it is possible that the population studied here is atypical of pharmacists in other jurisdictions or that the sample size is too small to make robust conclusions of pharmacists' perceptions outside our jurisdiction.

Given the inherent difficulty of studying the value of discrete activities, the importance of absence of evidence of impact of some activities may be questioned if an activity seems important to be performed regardless of evidence of benefit. Nevertheless, our key finding is that there is discordance between pharmacists' perceived impact and published evidence of impact -- specific activities were perceived to be of low impact (and thus presumably less time is spent on these) when actually there is published evidence of benefit. Similarly, pharmacists spend time on activities of unknown impact. We suggest that this discordance be minimized in the interests of maximizing pharmacist' impact and efficiency

CONCLUSIONS {#S17}
===========

Hospital-based pharmacists provide a wide variety of services and they believe those services to be of value in improving patient outcomes. Pharmacists dedicate more of their clinical time to activities they perceive to have greater impact. However, these perceptions and how they spend their time do not correlate well with published evidence of patient impact, and a few misperceptions about impacts deserve correction. More rigorous research is needed to quantify the value of pharmacist services to the health care system, however designing such studies to isolate the value of specific activities will be challenging.
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